My Cancer Genome: Genetically Informed Cancer Medicine

  • Home
  • DIRECT
  • About Us
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Anaplastic Large Cell Lymphoma
  • Basal Cell Carcinoma
  • Bladder Cancer
  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colorectal Cancer
  • GIST
  • Gastric Cancer
  • Glioma
  • Inflammatory Myofibroblastic Tumor
  • Lung Cancer
  • Medulloblastoma
  • Melanoma
  • Myelodysplastic Syndromes
  • Neuroblastoma
  • Ovarian Cancer
  • Prostate Cancer
  • Rhabdomyosarcoma
  • Thymic Carcinoma
  • Thyroid Cancer
  • Molecular Medicine
    • Anticancer Agents
    • Circulating Tumor DNA
    • Detecting Gene Alterations in Cancers
    • Immunotherapy in Cancer
    • Overview of Targeted Therapies for Cancer
    • Pathways
    • Types of Molecular Tumor Testing
  • Take Our Survey
  • Glossary
  • News
  • Our Team
  • Acknowledgements

Chromatin Remodeling/DNA Methylation

The process of chromatin remodeling promotes the coordinated adjustment of chromatin structure to facilitate access to condensed regions of DNA for activation of gene transcription and control of gene expression. Chromatin remodeling is achieved through histone modifications such as DNA methylation, an epigenetic control mechanism that switches genes on and off. Chromatin remodeling may be activated or inhibited by DNA methylation and is carried out by histone methyltransferases.

Chromatin Remodeling Color

Figure 1. DNA methylation is an epigenetic process of chromatin remodeling that regulates gene expression. Methylation of cytosine residues by DNA methyltransferase represses transcription and switches genes off. The addition of acetyl groups to histones by histone acetylase activates transcription and switches gene on. Specific nodes in the pathway that are therapeutically actionable are noted. Click here to open a larger version of this image in a new window.

Diseases in Which Pathway is Aberrantly Activated

  • Acute myeloid leukemia

Therapies That Target This Pathway

  • DNMT inhibitors
  • Histone deactylase

Genes Involved in Pathway

  • ASXL1
  • DNMT3A
  • DOT1L
  • EZH2
  • IDH1
  • IDH2
  • IKZF1
  • KAT6A
  • KDM5A
  • KDM5C
  • KDM6A
  • KMT2D (MLL2)
  • MRE11A
  • MSH2
  • MSH6
  • PBRM1
  • SETD2
  • TET2

Fusion Genes Involved in the Pathway

  • DEK-NUP214
  • MLL-MLLT3
  • RBM15-MKL1

Last Updated: May 24, 2016

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.

  • MCG Home |
  • About Us |
  • Acknowledgments |
  • Give |
  • Site Map |
  • Legal |
  • APIs and Licensing
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center   Copyright © 2010 - 2017 MY CANCER GENOME